Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | PHI-101 |
Trade Name | |
Synonyms | PHI101|PHI 101 |
Drug Descriptions |
PHI-101 is a Chk2 inhibitor with additional activity against FLT3, which potentially results in antitumor activity (Cancer Res 2021;81(13_Suppl):Abstract nr 1461, Cancer Res 2020;80(16 Suppl):Abstract nr 4226). |
DrugClasses | CHK2 Inhibitor 7 FLT3 Inhibitor 69 |
CAS Registry Number | 2127107-15-5 |
NCIT ID | C179279 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Olaparib + PHI-101 | Olaparib PHI-101 | 0 | 0 |
PHI-101 | PHI-101 | 9 | 0 |